A new analysis in Nature Mental Health is putting psychiatric pharmacists at the center of one of the most rapidly expanding—and controversial—frontiers in medicine: psychedelic therapy. The article, authored by Jenkins, Catanzano, Vadiei and colleagues, examines how pharmacists in the United States could help shape the safe development, clinical delivery and long-term monitoring of treatments involving substances such as psilocybin and 3,4-methylenedioxymethamphetamine, commonly known as MDMA. Rather than presenting psychedelics as simple “breakthrough drugs,” the authors describe them as complex therapeutic systems that combine pharmacology, psychological support, clinical supervision and carefully controlled environments. Their review arrives as public interest, investment and regulatory attention accelerate around psychedelic-assisted care for conditions that remain difficult to treat, including severe depression, post-traumatic stress disorder and substance-use disorders.
The scientific appeal of psychedelic therapy lies partly in the unusual way these compounds appear to alter brain function. Classic psychedelics such as psilocybin are converted in the body into active compounds that interact strongly with the serotonin 5-HT2A receptor, a signaling protein found throughout the cerebral cortex. This interaction can temporarily disrupt highly stable patterns of brain activity and alter perception, emotion, self-referential thought and the sense of time. Researchers have proposed that these changes may create a period of increased psychological flexibility, sometimes described as an opportunity for “relearning” or behavioral change. Other mechanisms under investigation include effects on glutamate signaling, emotional processing and structural plasticity—the capacity of neurons to modify their connections. Yet these biological effects do not operate in isolation. The therapeutic outcome may depend heavily on preparation, supervision and integration after the acute drug experience.
That combination makes psychedelic treatment fundamentally different from conventional medication management. A standard antidepressant is generally taken repeatedly, with pharmacists monitoring adherence, side effects, interactions and dose adjustments over time. Psychedelic-assisted therapy may instead involve a small number of closely supervised sessions, each potentially lasting several hours and producing profound changes in consciousness. The treatment model can also include psychological preparation before dosing and follow-up sessions intended to help patients interpret and apply what they experienced. Psychiatric pharmacists, the authors argue, are positioned to connect these phases. Their expertise in pharmacokinetics, pharmacodynamics, medication safety and patient education could help transform an unpredictable and highly individualized intervention into a more consistent clinical process.
One of the most immediate responsibilities would be medication assessment. Patients considered for psychedelic therapy may already be taking antidepressants, antipsychotics, mood stabilizers, sleep medications or drugs for cardiovascular conditions. These medicines can influence neurotransmitter systems, alter blood pressure or heart rate, change the intensity of psychedelic effects or complicate the interpretation of treatment outcomes. Selective serotonin reuptake inhibitors, for example, affect serotonin signaling and may modify a patient’s response to serotonergic psychedelics, although the clinical significance of that interaction is still being studied. Pharmacists could review a patient’s complete medication history, identify potential contraindications, advise clinicians about risks and help prevent unsafe, unsupervised discontinuation of essential medicines. Such decisions would require individualized assessment rather than blanket rules.
Safety screening is particularly important because psychedelic experiences can include acute anxiety, confusion, elevated blood pressure, nausea, dizziness and intense emotional reactions. In vulnerable individuals, psychoactive exposure may also worsen psychiatric symptoms or trigger severe destabilization. Patients with a history of psychotic disorders, mania or certain cardiovascular conditions may require exclusion or specialized evaluation, depending on the substance and treatment protocol. Pharmacists could contribute to screening procedures, emergency planning and real-time monitoring during dosing sessions. They may also help establish protocols for managing agitation, panic, hypertension or other adverse events. The goal would not be to eliminate every challenging psychological experience—some therapeutic models view difficult emotions as potentially meaningful—but to distinguish a clinically manageable reaction from a medical or psychiatric emergency.
The article also highlights a central policy problem in the United States: psychedelic care is developing faster than a uniform national infrastructure for delivering it. Regulatory status differs among compounds, research settings and jurisdictions, while professional roles and training requirements remain unsettled. A treatment may involve prescribers, therapists, nurses, pharmacists, psychologists and specialized support staff, but responsibility for each stage is not always clearly defined. Psychiatric pharmacists could help build standardized procedures for procurement, storage, preparation, dispensing, administration and documentation. Their involvement may be especially important for controlled substances, where secure handling, inventory tracking and diversion prevention are essential. By participating in institutional policy design, pharmacists could help ensure that new services meet legal requirements without reducing therapy to a purely logistical exercise.
Training will be another decisive factor. Psychedelic therapy requires knowledge that extends beyond traditional psychopharmacology. Clinicians must understand receptor activity, dose-response relationships, metabolism and drug interactions, but they must also recognize how expectations, trauma history, cultural background and the treatment environment influence patient experiences. The authors’ discussion suggests that future psychiatric pharmacists may need education in psychedelic pharmacology, risk assessment, therapeutic communication, trauma-informed care and the ethics of altered states of consciousness. They would not necessarily replace therapists or become the sole providers of treatment. Instead, their role could resemble that of a medication-safety and pharmacotherapy specialist embedded within a multidisciplinary team, helping ensure that the biological intervention and the psychological intervention remain coordinated.
Evidence quality will determine whether the field moves from cultural phenomenon to reliable medicine. Enthusiasm for psychedelics has been fueled by promising early studies, but many questions remain unresolved. Researchers must determine which patients benefit most, how long improvements last, whether repeated treatment is necessary and which elements of the therapeutic setting are essential. Clinical trials must also account for expectancy effects, because participants may correctly guess whether they received an active psychedelic, potentially influencing reported outcomes. Long-term monitoring is needed to assess persistent benefits as well as rare or delayed harms. Psychiatric pharmacists could support this research by helping standardize medication protocols, document adverse events, evaluate concomitant therapies and monitor outcomes after treatment. Their participation may improve the comparability of studies and strengthen the evidence used by regulators and health systems.
Access and equity form another major concern. Psychedelic therapy is likely to require substantial staff time, specialized facilities and extended monitoring, factors that could make treatment expensive and difficult to obtain. If services are concentrated in private clinics or major academic centers, patients in rural communities and those without comprehensive insurance may be left behind. Cultural and social factors also matter: the meaning of psychedelic experiences can vary widely, and communities with histories of medical exploitation may understandably approach new therapies with caution. Pharmacists working in psychiatric care could contribute to transparent consent processes, culturally responsive education and fair medication-use policies. They may also help identify patients who are being excluded by rigid protocols without a strong scientific justification, while maintaining appropriate safeguards for those at elevated risk.
The future envisioned by the review is therefore not a world in which psychedelics replace existing psychiatric medicines, but one in which carefully selected patients may receive another evidence-based option within a tightly controlled care model. Psychiatric pharmacists could become key architects of that model, translating rapidly evolving laboratory findings into practical rules for screening, dosing, interaction management, monitoring and follow-up. Their involvement may also help counter the industry’s most dangerous temptation: treating a powerful psychoactive experience as a shortcut to healing. For psychedelic therapy to become credible mainstream medicine, dramatic personal stories will not be enough. Success will depend on reproducible evidence, ethical safeguards, multidisciplinary teamwork and professionals capable of managing both the chemistry of the drug and the complexity of the patient. In that emerging system, the pharmacist’s role may be far more central than the public conversation has so far recognized.
Subject of Research: The current and future roles of psychiatric pharmacists in psychedelic-assisted therapy in the United States.
Article Title: Psychedelic therapy and the current and future roles for psychiatric pharmacists in the USA.
Article References: Jenkins, J., Catanzano, S., Vadiei, N. et al. “Psychedelic therapy and the current and future roles for psychiatric pharmacists in the USA.” Nature Mental Health (2026). https://doi.org/10.1038/s44220-026-00709-2
Image Credits: AI Generated
DOI: 10.1038/s44220-026-00709-2
Keywords: Psychedelic therapy, psychiatric pharmacists, psilocybin, MDMA, pharmacology, mental health, drug interactions, patient safety, psychiatric care, United States.
